Cargando…

Aggressive Angiomyxoma of the Lower Female Genital Tract in Pregnancy: A Review of the MITO Rare Tumors Group

SIMPLE SUMMARY: Deep (aggressive) angiomyxoma (DAM) is an extremely rare primary neoplasm of the vulva whose growth is particularly favored during pregnancy. To date, neither the origin nor the optimal management of DAM are clear, especially in pregnancy. Therefore, we present here a systematic revi...

Descripción completa

Detalles Bibliográficos
Autores principales: Cicogna, Stefania, Dellino, Miriam, Miano, Salvatora Tindara, Magazzino, Francescapaola, Domenici, Lavinia, Pignata, Sandro, Mangili, Giorgia, Cormio, Gennaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340504/
https://www.ncbi.nlm.nih.gov/pubmed/37444513
http://dx.doi.org/10.3390/cancers15133403
_version_ 1785072095552602112
author Cicogna, Stefania
Dellino, Miriam
Miano, Salvatora Tindara
Magazzino, Francescapaola
Domenici, Lavinia
Pignata, Sandro
Mangili, Giorgia
Cormio, Gennaro
author_facet Cicogna, Stefania
Dellino, Miriam
Miano, Salvatora Tindara
Magazzino, Francescapaola
Domenici, Lavinia
Pignata, Sandro
Mangili, Giorgia
Cormio, Gennaro
author_sort Cicogna, Stefania
collection PubMed
description SIMPLE SUMMARY: Deep (aggressive) angiomyxoma (DAM) is an extremely rare primary neoplasm of the vulva whose growth is particularly favored during pregnancy. To date, neither the origin nor the optimal management of DAM are clear, especially in pregnancy. Therefore, we present here a systematic review that could be a useful tool to provide further knowledge about the behavior of and the management strategies for this rare malignancy. ABSTRACT: Deep (aggressive) angiomyxoma of the lower genital tract is a rare malignancy affecting women of reproductive age. Being a hormone-sensitive tumor, its growth is particularly benefitted during pregnancy. Surgical excision with complete resection is indicated, even if a wait-and-see approach can be considered until delivery, to avoid destructive surgeries. The mode of delivery is to be evaluated based on the location and size of the neoplasm; vaginal delivery is not contraindicated, as long as the tumor does not obstruct the birth canal. Positive surgical margins are the most important prognostic factor for recurrence. Adjuvant therapy with gonadotropin-releasing hormone analogues may be proposed after pregnancy, in the case of non-radical surgery. Despite the high local relapse rate, the outcomes for mother and child are favorable. Since recurrences can occur after many years, the patient should be included in long-term follow-up.
format Online
Article
Text
id pubmed-10340504
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103405042023-07-14 Aggressive Angiomyxoma of the Lower Female Genital Tract in Pregnancy: A Review of the MITO Rare Tumors Group Cicogna, Stefania Dellino, Miriam Miano, Salvatora Tindara Magazzino, Francescapaola Domenici, Lavinia Pignata, Sandro Mangili, Giorgia Cormio, Gennaro Cancers (Basel) Review SIMPLE SUMMARY: Deep (aggressive) angiomyxoma (DAM) is an extremely rare primary neoplasm of the vulva whose growth is particularly favored during pregnancy. To date, neither the origin nor the optimal management of DAM are clear, especially in pregnancy. Therefore, we present here a systematic review that could be a useful tool to provide further knowledge about the behavior of and the management strategies for this rare malignancy. ABSTRACT: Deep (aggressive) angiomyxoma of the lower genital tract is a rare malignancy affecting women of reproductive age. Being a hormone-sensitive tumor, its growth is particularly benefitted during pregnancy. Surgical excision with complete resection is indicated, even if a wait-and-see approach can be considered until delivery, to avoid destructive surgeries. The mode of delivery is to be evaluated based on the location and size of the neoplasm; vaginal delivery is not contraindicated, as long as the tumor does not obstruct the birth canal. Positive surgical margins are the most important prognostic factor for recurrence. Adjuvant therapy with gonadotropin-releasing hormone analogues may be proposed after pregnancy, in the case of non-radical surgery. Despite the high local relapse rate, the outcomes for mother and child are favorable. Since recurrences can occur after many years, the patient should be included in long-term follow-up. MDPI 2023-06-29 /pmc/articles/PMC10340504/ /pubmed/37444513 http://dx.doi.org/10.3390/cancers15133403 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Cicogna, Stefania
Dellino, Miriam
Miano, Salvatora Tindara
Magazzino, Francescapaola
Domenici, Lavinia
Pignata, Sandro
Mangili, Giorgia
Cormio, Gennaro
Aggressive Angiomyxoma of the Lower Female Genital Tract in Pregnancy: A Review of the MITO Rare Tumors Group
title Aggressive Angiomyxoma of the Lower Female Genital Tract in Pregnancy: A Review of the MITO Rare Tumors Group
title_full Aggressive Angiomyxoma of the Lower Female Genital Tract in Pregnancy: A Review of the MITO Rare Tumors Group
title_fullStr Aggressive Angiomyxoma of the Lower Female Genital Tract in Pregnancy: A Review of the MITO Rare Tumors Group
title_full_unstemmed Aggressive Angiomyxoma of the Lower Female Genital Tract in Pregnancy: A Review of the MITO Rare Tumors Group
title_short Aggressive Angiomyxoma of the Lower Female Genital Tract in Pregnancy: A Review of the MITO Rare Tumors Group
title_sort aggressive angiomyxoma of the lower female genital tract in pregnancy: a review of the mito rare tumors group
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340504/
https://www.ncbi.nlm.nih.gov/pubmed/37444513
http://dx.doi.org/10.3390/cancers15133403
work_keys_str_mv AT cicognastefania aggressiveangiomyxomaofthelowerfemalegenitaltractinpregnancyareviewofthemitoraretumorsgroup
AT dellinomiriam aggressiveangiomyxomaofthelowerfemalegenitaltractinpregnancyareviewofthemitoraretumorsgroup
AT mianosalvatoratindara aggressiveangiomyxomaofthelowerfemalegenitaltractinpregnancyareviewofthemitoraretumorsgroup
AT magazzinofrancescapaola aggressiveangiomyxomaofthelowerfemalegenitaltractinpregnancyareviewofthemitoraretumorsgroup
AT domenicilavinia aggressiveangiomyxomaofthelowerfemalegenitaltractinpregnancyareviewofthemitoraretumorsgroup
AT pignatasandro aggressiveangiomyxomaofthelowerfemalegenitaltractinpregnancyareviewofthemitoraretumorsgroup
AT mangiligiorgia aggressiveangiomyxomaofthelowerfemalegenitaltractinpregnancyareviewofthemitoraretumorsgroup
AT cormiogennaro aggressiveangiomyxomaofthelowerfemalegenitaltractinpregnancyareviewofthemitoraretumorsgroup